- Home
- BLNK vs ADCT Comparison
BLNK vs ADCT Comparison
Compare BLNK & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- ADCT
- Stock Information
- Founded
- BLNK 2009
- ADCT 2011
- Country
- BLNK United States
- ADCT Switzerland
- Employees
- BLNK N/A
- ADCT N/A
- Industry
- BLNK Industrial Specialties
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- BLNK Consumer Discretionary
- ADCT Health Care
- Exchange
- BLNK Nasdaq
- ADCT Nasdaq
- Market Cap
- BLNK 77.3M
- ADCT 241.0M
- IPO Year
- BLNK N/A
- ADCT 2020
- Fundamental
- Price
- BLNK $1.06
- ADCT $3.08
- Analyst Decision
- BLNK Buy
- ADCT Strong Buy
- Analyst Count
- BLNK 8
- ADCT 6
- Target Price
- BLNK $2.61
- ADCT $7.80
- AVG Volume (30 Days)
- BLNK 4.2M
- ADCT 865.5K
- Earning Date
- BLNK 08-06-2025
- ADCT 08-05-2025
- Dividend Yield
- BLNK N/A
- ADCT N/A
- EPS Growth
- BLNK N/A
- ADCT N/A
- EPS
- BLNK N/A
- ADCT N/A
- Revenue
- BLNK $109,383,000.00
- ADCT $75,817,000.00
- Revenue This Year
- BLNK N/A
- ADCT $11.75
- Revenue Next Year
- BLNK $31.15
- ADCT $10.29
- P/E Ratio
- BLNK N/A
- ADCT N/A
- Revenue Growth
- BLNK N/A
- ADCT 10.49
- 52 Week Low
- BLNK $0.63
- ADCT $1.05
- 52 Week High
- BLNK $3.62
- ADCT $3.98
- Technical
- Relative Strength Index (RSI)
- BLNK 54.55
- ADCT 54.11
- Support Level
- BLNK $0.92
- ADCT $3.04
- Resistance Level
- BLNK $1.02
- ADCT $3.39
- Average True Range (ATR)
- BLNK 0.06
- ADCT 0.21
- MACD
- BLNK -0.00
- ADCT 0.00
- Stochastic Oscillator
- BLNK 43.93
- ADCT 67.07
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).